$NVIV Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INVIVO THERAPEUTICS HOLDINGS CORP..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INVIVO THERAPEUTICS HOLDINGS CORP.. Get notifications about new insider transactions in INVIVO THERAPEUTICS HOLDINGS CORP. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.31 | 1,000 | 2,310 | 13,551,810 | 13.6 M to 13.6 M (-0.01 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.30 | 2,250 | 5,175 | 13,552,810 | 13.6 M to 13.6 M (-0.02 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.18 | 4,250 | 9,265 | 13,555,060 | 13.6 M to 13.6 M (-0.03 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.13 | 2,250 | 4,793 | 13,559,310 | 13.6 M to 13.6 M (-0.02 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.08 | 1,000 | 2,080 | 13,561,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.07 | 1,000 | 2,070 | 13,562,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.03 | 1,000 | 2,030 | 13,563,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.02 | 1,000 | 2,020 | 13,564,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.01 | 2,250 | 4,523 | 13,565,560 | 13.6 M to 13.6 M (-0.02 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.88 | 1,250 | 2,350 | 13,567,810 | 13.6 M to 13.6 M (-0.01 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.85 | 3,000 | 5,550 | 13,569,060 | 13.6 M to 13.6 M (-0.02 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.81 | 1,000 | 1,810 | 13,572,060 | 13.6 M to 13.6 M (-0.01 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.80 | 3,250 | 5,850 | 13,573,060 | 13.6 M to 13.6 M (-0.02 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.71 | 4,250 | 7,268 | 13,576,310 | 13.6 M to 13.6 M (-0.03 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.69 | 1,000 | 1,690 | 13,580,560 | 13.6 M to 13.6 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.68 | 390 | 655 | 13,581,560 | 13.6 M to 13.6 M (0.00 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 660 | 1,089 | 13,581,950 | 13.6 M to 13.6 M (0.00 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.64 | 2,200 | 3,608 | 13,582,610 | 13.6 M to 13.6 M (-0.02 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Gift | G | 0.00 | 171,000 | 0 | 13,584,810 | 13.8 M to 13.6 M (-1.24 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.70 | 1,000 | 1,700 | 13,755,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.69 | 1,000 | 1,690 | 13,756,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.68 | 1,000 | 1,680 | 13,757,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 50 | 83 | 13,758,860 | 13.8 M to 13.8 M (0.00 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.64 | 1,200 | 1,968 | 13,758,860 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.79 | 20 | 36 | 13,760,060 | 13.8 M to 13.8 M (0.00 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.75 | 1,230 | 2,153 | 13,760,080 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.73 | 3,000 | 5,190 | 13,761,310 | 13.8 M to 13.8 M (-0.02 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.84 | 1,000 | 1,840 | 13,764,310 | 13.8 M to 13.8 M (-0.01 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.74 | 1,000 | 1,740 | 13,765,310 | 13.8 M to 13.8 M (-0.01 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.68 | 2,250 | 3,780 | 13,766,310 | 13.8 M to 13.8 M (-0.02 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.99 | 1,250 | 2,488 | 13,768,560 | 13.8 M to 13.8 M (-0.01 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.97 | 1,000 | 1,970 | 13,769,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.91 | 1,000 | 1,910 | 13,770,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.90 | 1,000 | 1,900 | 13,771,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.73 | 100 | 173 | 13,772,810 | 13.8 M to 13.8 M (0.00 %) |
Feb 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.72 | 4,150 | 7,138 | 13,772,910 | 13.8 M to 13.8 M (-0.03 %) |
Feb 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.04 | 3,000 | 6,120 | 14,193,810 | 14.2 M to 14.2 M (-0.02 %) |
Feb 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.02 | 1,250 | 2,525 | 14,196,810 | 14.2 M to 14.2 M (-0.01 %) |
Feb 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.15 | 2,000 | 4,300 | 14,198,060 | 14.2 M to 14.2 M (-0.01 %) |
Feb 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.01 | 2,250 | 4,523 | 14,200,060 | 14.2 M to 14.2 M (-0.02 %) |
Feb 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.01 | 1,000 | 2,010 | 14,202,310 | 14.2 M to 14.2 M (-0.01 %) |
Feb 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.00 | 3,250 | 6,500 | 14,203,310 | 14.2 M to 14.2 M (-0.02 %) |
Feb 13 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.82 | 4,250 | 7,735 | 13,777,060 | 13.8 M to 13.8 M (-0.03 %) |
Feb 13 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.94 | 4,250 | 8,245 | 13,781,310 | 13.8 M to 13.8 M (-0.03 %) |
Feb 13 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Gift | G | 0.00 | 404,000 | 0 | 13,785,560 | 14.2 M to 13.8 M (-2.85 %) |
Feb 13 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.99 | 1,000 | 1,990 | 14,189,560 | 14.2 M to 14.2 M (-0.01 %) |
Feb 13 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.98 | 3,250 | 6,435 | 14,190,560 | 14.2 M to 14.2 M (-0.02 %) |
Feb 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.05 | 4,250 | 8,713 | 14,206,560 | 14.2 M to 14.2 M (-0.03 %) |
Feb 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.04 | 1,000 | 2,040 | 14,210,810 | 14.2 M to 14.2 M (-0.01 %) |
Feb 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.98 | 1,355 | 2,683 | 14,211,810 | 14.2 M to 14.2 M (-0.01 %) |
Feb 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.97 | 1,895 | 3,733 | 14,213,165 | 14.2 M to 14.2 M (-0.01 %) |
Feb 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.04 | 4,250 | 8,670 | 14,215,060 | 14.2 M to 14.2 M (-0.03 %) |
Jan 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.05 | 1,500 | 3,075 | 14,219,310 | 14.2 M to 14.2 M (-0.01 %) |
Jan 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.04 | 700 | 1,428 | 14,220,810 | 14.2 M to 14.2 M (0.00 %) |
Jan 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.02 | 2,050 | 4,141 | 14,221,510 | 14.2 M to 14.2 M (-0.01 %) |
Jan 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.36 | 1,100 | 2,596 | 14,223,560 | 14.2 M to 14.2 M (-0.01 %) |
Jan 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.45 | 4,250 | 10,413 | 14,224,660 | 14.2 M to 14.2 M (-0.03 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.45 | 4,250 | 10,413 | 14,241,660 | 14.2 M to 14.2 M (-0.03 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.53 | 50 | 127 | 14,245,910 | 14.2 M to 14.2 M (0.00 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.52 | 1,200 | 3,024 | 14,245,960 | 14.2 M to 14.2 M (-0.01 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.50 | 3,000 | 7,500 | 14,247,160 | 14.3 M to 14.2 M (-0.02 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.48 | 2,000 | 4,960 | 14,250,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.46 | 1,000 | 2,460 | 14,252,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 23 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.43 | 1,250 | 3,038 | 14,253,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.38 | 4,250 | 10,115 | 14,228,910 | 14.2 M to 14.2 M (-0.03 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.44 | 41 | 100 | 14,233,160 | 14.2 M to 14.2 M (0.00 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.43 | 30 | 73 | 14,233,201 | 14.2 M to 14.2 M (0.00 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.41 | 1,929 | 4,649 | 14,233,231 | 14.2 M to 14.2 M (-0.01 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.40 | 1,250 | 3,000 | 14,235,160 | 14.2 M to 14.2 M (-0.01 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.37 | 1,000 | 2,370 | 14,236,410 | 14.2 M to 14.2 M (-0.01 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.50 | 1,000 | 2,500 | 14,237,410 | 14.2 M to 14.2 M (-0.01 %) |
Jan 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.48 | 3,250 | 8,060 | 14,238,410 | 14.2 M to 14.2 M (-0.02 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.52 | 1,250 | 3,150 | 14,254,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.51 | 1,000 | 2,510 | 14,255,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.50 | 2,000 | 5,000 | 14,256,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.48 | 2,250 | 5,580 | 14,258,660 | 14.3 M to 14.3 M (-0.02 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.47 | 1,000 | 2,470 | 14,260,910 | 14.3 M to 14.3 M (-0.01 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.46 | 1,000 | 2,460 | 14,261,910 | 14.3 M to 14.3 M (-0.01 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.42 | 3,250 | 7,865 | 14,262,910 | 14.3 M to 14.3 M (-0.02 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.40 | 1,000 | 2,400 | 14,266,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | LANGER ROBERT | 10% Owner | Sell | S | 2.46 | 52,425 | 129,076 | 7,506,378 | 7.6 M to 7.5 M (-0.69 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | LANGER ROBERT | 10% Owner | Sell | S | 2.46 | 102,874 | 253,523 | 7,558,803 | 7.7 M to 7.6 M (-1.34 %) |
Jan 17 2013 | NVIV | INVIVO THERAPEUTIC ... | LANGER ROBERT | 10% Owner | Sell | S | 2.47 | 35,436 | 87,587 | 7,661,677 | 7.7 M to 7.7 M (-0.46 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.38 | 1,250 | 2,975 | 14,267,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.35 | 2,000 | 4,700 | 14,268,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.32 | 1,000 | 2,320 | 14,270,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.30 | 1,000 | 2,300 | 14,271,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.23 | 1,250 | 2,788 | 14,272,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.22 | 1,000 | 2,220 | 14,273,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.21 | 1,000 | 2,210 | 14,274,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.40 | 1,000 | 2,400 | 14,275,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.38 | 1,000 | 2,380 | 14,276,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.32 | 100 | 232 | 14,277,660 | 14.3 M to 14.3 M (0.00 %) |
Jan 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.31 | 2,150 | 4,967 | 14,277,760 | 14.3 M to 14.3 M (-0.02 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.25 | 2,250 | 5,063 | 14,279,910 | 14.3 M to 14.3 M (-0.02 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.17 | 2,000 | 4,340 | 14,282,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.12 | 2,250 | 4,770 | 14,284,160 | 14.3 M to 14.3 M (-0.02 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.07 | 1,000 | 2,070 | 14,286,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.06 | 1,000 | 2,060 | 14,287,410 | 14.3 M to 14.3 M (-0.01 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.96 | 2,250 | 4,410 | 14,288,410 | 14.3 M to 14.3 M (-0.02 %) |
Jan 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.90 | 2,000 | 3,800 | 14,290,660 | 14.3 M to 14.3 M (-0.01 %) |
Jan 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.75 | 4,250 | 7,438 | 14,292,660 | 14.3 M to 14.3 M (-0.03 %) |
Jan 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.86 | 3,780 | 7,031 | 14,296,910 | 14.3 M to 14.3 M (-0.03 %) |
Jan 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.85 | 470 | 870 | 14,300,690 | 14.3 M to 14.3 M (0.00 %) |
Jan 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.80 | 800 | 1,440 | 14,301,160 | 14.3 M to 14.3 M (-0.01 %) |
Jan 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.78 | 2,250 | 4,005 | 14,301,960 | 14.3 M to 14.3 M (-0.02 %) |
Jan 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.77 | 1,200 | 2,124 | 14,304,210 | 14.3 M to 14.3 M (-0.01 %) |
Jan 02 2013 | NVIV | INVIVO THERAPEUTIC ... | NOLEN GEORGE | Director | Option Exercise | A | 1.73 | 50,000 | 86,500 | 50,000 | |
Dec 31 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.84 | 2,000 | 3,680 | 14,305,410 | 14.3 M to 14.3 M (-0.01 %) |
Dec 31 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.80 | 2,250 | 4,050 | 14,307,410 | 14.3 M to 14.3 M (-0.02 %) |
Dec 31 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.85 | 2,250 | 4,163 | 14,309,660 | 14.3 M to 14.3 M (-0.02 %) |
Dec 31 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.82 | 2,000 | 3,630 | 14,311,910 | 14.3 M to 14.3 M (-0.01 %) |
Dec 31 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.80 | 4,250 | 7,650 | 14,313,910 | 14.3 M to 14.3 M (-0.03 %) |
Dec 26 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 4,250 | 7,013 | 14,318,160 | 14.3 M to 14.3 M (-0.03 %) |
Dec 26 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.64 | 2,250 | 3,690 | 14,322,410 | 14.3 M to 14.3 M (-0.02 %) |
Dec 26 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.63 | 2,000 | 3,260 | 14,324,660 | 14.3 M to 14.3 M (-0.01 %) |
Dec 26 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.63 | 500 | 815 | 14,326,660 | 14.3 M to 14.3 M (0.00 %) |
Dec 26 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.62 | 3,750 | 6,075 | 14,327,160 | 14.3 M to 14.3 M (-0.03 %) |
Dec 21 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.64 | 2,000 | 3,280 | 14,330,910 | 14.3 M to 14.3 M (-0.01 %) |
Dec 21 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.62 | 2,250 | 3,645 | 14,332,910 | 14.3 M to 14.3 M (-0.02 %) |
Dec 21 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 1,200 | 1,980 | 14,335,160 | 14.3 M to 14.3 M (-0.01 %) |
Dec 21 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.62 | 800 | 1,296 | 14,336,360 | 14.3 M to 14.3 M (-0.01 %) |
Dec 21 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.61 | 600 | 966 | 14,337,160 | 14.3 M to 14.3 M (0.00 %) |
Dec 21 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.60 | 1,650 | 2,640 | 14,337,760 | 14.3 M to 14.3 M (-0.01 %) |
Dec 20 2012 | NVIV | INVIVO THERAPEUTIC ... | DiPietro Kenneth | Director | Option Exercise | A | 1.65 | 50,000 | 82,500 | 50,000 | |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | STERN ADAM K | Director | Option Exercise | A | 1.73 | 50,000 | 86,500 | 50,000 | |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.63 | 1,250 | 2,038 | 14,339,410 | 14.3 M to 14.3 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 1,000 | 1,650 | 14,340,660 | 14.3 M to 14.3 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.61 | 2,000 | 3,220 | 14,341,660 | 14.3 M to 14.3 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.63 | 1,000 | 1,630 | 14,343,660 | 14.3 M to 14.3 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.60 | 3,250 | 5,200 | 14,344,660 | 14.3 M to 14.3 M (-0.02 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.60 | 500 | 800 | 14,347,910 | 14.3 M to 14.3 M (0.00 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.63 | 500 | 815 | 14,348,410 | 14.3 M to 14.3 M (0.00 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.66 | 1,500 | 2,490 | 14,348,910 | 14.4 M to 14.3 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.73 | 1,000 | 1,730 | 14,350,410 | 14.4 M to 14.4 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 750 | 1,238 | 14,351,410 | 14.4 M to 14.4 M (-0.01 %) |
Dec 18 2012 | NVIV | INVIVO THERAPEUTIC ... | ROBERTS RICHARD JOHN | Director | Option Exercise | A | 1.73 | 50,000 | 86,500 | 50,000 | |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.60 | 4,250 | 6,800 | 14,352,160 | 14.4 M to 14.4 M (-0.03 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.70 | 1,650 | 2,805 | 14,356,410 | 14.4 M to 14.4 M (-0.01 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 350 | 578 | 14,358,060 | 14.4 M to 14.4 M (0.00 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.62 | 700 | 1,134 | 14,358,410 | 14.4 M to 14.4 M (0.00 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.61 | 1,550 | 2,496 | 14,359,110 | 14.4 M to 14.4 M (-0.01 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.73 | 800 | 1,384 | 14,360,660 | 14.4 M to 14.4 M (-0.01 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.70 | 30 | 51 | 14,361,460 | 14.4 M to 14.4 M (0.00 %) |
Dec 13 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.67 | 3,420 | 5,711 | 14,361,490 | 14.4 M to 14.4 M (-0.02 %) |
Dec 10 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.67 | 300 | 501 | 14,364,910 | 14.4 M to 14.4 M (0.00 %) |
Dec 10 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.66 | 3,950 | 6,557 | 14,365,210 | 14.4 M to 14.4 M (-0.03 %) |
Dec 10 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.69 | 2,500 | 4,225 | 14,369,160 | 14.4 M to 14.4 M (-0.02 %) |
Dec 10 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.68 | 1,500 | 2,520 | 14,371,660 | 14.4 M to 14.4 M (-0.01 %) |
Dec 10 2012 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.67 | 250 | 418 | 14,373,160 | 14.4 M to 14.4 M (0.00 %) |